DNA molecule, illustration.
Our Work

Latham & Watkins Advises Unlearn in US$50 Million Series C Financing

February 8, 2024
Emerging Companies & Growth team represented the AI company in latest funding round.

Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, has announced a US$50 Million Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company’s mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering capabilities, and longer-term R&D initiatives.

Latham & Watkins LLP advised Unlearn in the financing with an Emerging Companies & Growth team led by Boston partner Dan Hoffman, with associates Martha Anderson, Sally Gu, and Michael Pioso. Advice was also provided on compensation and benefits matters by Bay Area partner Ashley Wagner. This follows Latham’s representation of Unlearn in its Series B in April 2022.